BiondVax – executive interview

BiondVax – executive interview

BiondVax (Nasdaq: BVXV) is a biopharmaceutical company focused on developing, manufacturing and commercialising innovative products for the prevention and treatment of infectious diseases and other illnesses. It is developing a pipeline of innovative nanosized antibody (NanoAb) therapies addressing diseases such as COVID-19, asthma and psoriasis.

In this interview, Dalit Weinstein Fischer, head of Technical R&D at BiondVax, discusses the company’s NanoAb development process and BiondVax’s GMP manufacturing facility.

You may also be interested in these:

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free